Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis
Ke Feng, Chuanrui Ma, Yuxin Liu, Xiaoxiao Yang, Zhimou Yang, Yaoxia Chen, Tengyan Xu, Chengbiao Yang, Shuang Zhang, Qi Li, Wei Zhuo, Dan Zhao, Peng Zeng, Jihong Han, Jie Gao, Yuanli Chen, Yajun Duan
Abstract
Our study demonstrates that D-Nap-GFFY-T317 inhibits lung tumor growth without adverse effects on the liver, indicating the hydrogel-encapsulated LXR ligand might be a novel therapy for tumor treatment.
Topics & Concepts
NapLipogenesisChemistryLiver X receptorCancer researchInterferonEndocrinologyInternal medicineLipid metabolismBiologyImmunologyMedicineBiochemistryNuclear receptorTranscription factorNeuroscienceGeneCholesterol and Lipid MetabolismCancer, Lipids, and Metabolisminterferon and immune responses